HealthMore in Health→
KRAS Vaccine Shows Immune Response in Pancreatic Trial
Key Takeaways
- The phase 2 trial enrolled 144 patients with stage 1–3 KRAS-mutated pancreatic cancer.
- The vaccine targets seven common KRAS mutations and is designed as an off-the-shelf treatment.
- Stronger immune responses were associated with longer disease-free survival in an exploratory analysis.
DE
DT Editorial Team··via medicalxpress.com
